<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02885753</url>
  </required_header>
  <id_info>
    <org_study_id>PRODIGE 49</org_study_id>
    <nct_id>NCT02885753</nct_id>
  </id_info>
  <brief_title>Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver</brief_title>
  <acronym>OSCAR</acronym>
  <official_title>Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federation Francophone de Cancerologie Digestive</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federation Francophone de Cancerologie Digestive</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Colorectal cancer is the 3rd most common cancer in France and the 2nd cause of death from
      cancer. Between 30 to 60% of patients develop limited or predominant liver metastases.
      Surgical resection of these metastases, only curative treatment is not immediately possible
      in 10-15% of cases. In unresectable patients, current palliative treatments are based on
      systemic chemotherapy associated or not with the targeted therapies (anti-EGFR (panitumumab),
      anti-VEGF (bevacizumab)). In this patient population, special attention was paid to
      intensified treatment regimens in order to improve their efficiency and improving the tumoral
      response rate, the intensity of the response and its earliness correlate with improved
      overall and progression-free survival.

      The intra-arterial use of oxaliplatin coupled with IV chemotherapy has yielded OR levels of
      64% in patients having survived one or more lines of chemotherapy IV and 62% in patients who
      have progressed on oxaliplatin IV. In addition, the HIA administration of oxaliplatin limits
      systemic and especially neurological toxicities, thanks to a greater hepatic clearance.

      In conclusion, the combination of systemic chemotherapy, targeted therapy and HIAC with
      oxaliplatin has showed promising efficacy results associated with good tolerance from the
      first line onwards. Indeed, we can expect from the Phase II recent data, a control rate close
      to 100%, with high response rates associated with early maturity and depth responses as well
      as prolonged survival. However, to date, in the absence of randomized trial testing this
      combination, this strategy does not have sufficient evidence to be integrated in our routine
      practices, and HIAC remains limited to a few expert centers in treatment catch-up.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>hepatic progression-free survival</measure>
    <time_frame>24 months after randomization</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">268</enrollment>
  <condition>Colorectal Neoplasms</condition>
  <arm_group>
    <arm_group_label>Experimental arm with oxaliplatin intra-arterial</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Panitumumab (6 mg/kg if RAS wild) or Bevacizumab (5 mg/Kg if RAS mutated) Oxaliplatin (85 mg/m²) intra-arterially Folinic Acid (400 mg/m²) intravenously 5Fu: 400 mg/m² in bolus of 10 minutes 5Fu: 2400 mg/m² intravenously over 46 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference arm with oxaliplatin intravenous</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Panitumumab (6 mg/kg if RAS wild) or Bevacizumab (5 mg/Kg if RAS mutated) Oxaliplatin (85 mg/m²) intravenously Folinic Acid (400 mg/m²) intravenously 5Fu: 400 mg/m² in bolus of 10 minutes 5Fu: 2400 mg/m² intravenously over 46 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin intravenous</intervention_name>
    <description>85 mg/m² in intravenous. 1 cycle each 15 days</description>
    <arm_group_label>Reference arm with oxaliplatin intravenous</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5 Fu</intervention_name>
    <description>5 fluorouracil : 400 mg/m² in bolus of 10 minutes (intravenous) following by 2400 mg/m² during 46 hours in intravenous</description>
    <arm_group_label>Experimental arm with oxaliplatin intra-arterial</arm_group_label>
    <arm_group_label>Reference arm with oxaliplatin intravenous</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Folinic Acid</intervention_name>
    <description>400 mg/m² in intravenous</description>
    <arm_group_label>Experimental arm with oxaliplatin intra-arterial</arm_group_label>
    <arm_group_label>Reference arm with oxaliplatin intravenous</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin intra-arteriel</intervention_name>
    <description>85 mg/m² in intra-arterial. 1 cycle each 15 days</description>
    <arm_group_label>Experimental arm with oxaliplatin intra-arterial</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Panitumumab</intervention_name>
    <description>Only for patient RAS wild: 6 mg/Kg at each cycle in intravenous</description>
    <arm_group_label>Experimental arm with oxaliplatin intra-arterial</arm_group_label>
    <arm_group_label>Reference arm with oxaliplatin intravenous</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Only for patient RAS mutated : 5 mg/m² at each cycle in intravenous</description>
    <arm_group_label>Experimental arm with oxaliplatin intra-arterial</arm_group_label>
    <arm_group_label>Reference arm with oxaliplatin intravenous</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven colorectal adenocarcinoma with hepatic metastasis(es)

          -  At least one measurable hepatic metastasis according to the criteria RECIST v1.1

          -  No other metastatic sites except lung nodules if number ≤ 3 and &lt; 10 mm

          -  RAS mutation status known (determination of KRAS mutation (exons 2,3 and 4) and
             determination of the NRAS mutation (exons 2,3 and 4))

          -  Age ≥ 18

          -  WHO ≤ 2 (Appendix 4)

          -  No prior treatment by chemotherapy except perioperative or adjuvant chemotherapy
             discontinued for more than 12 months

          -  Life expectancy &gt; 3 months

          -  PNN &gt; 1500/mm3, platelets &gt; 100 000/mm3, Hb &gt; 9 g/dLq

          -  Bilirubin &lt; 25 mmol/L, AST &lt; 5x ULN, ALT &lt; 5 x ULN, ALP &lt; 5 x ULN, TP &gt; 60%,
             proteinuria from 24H &lt; 1 g

          -  Creatinine clearance &gt; 50 mL/min according to MDRD formula (Appendix 4)

          -  Patient affiliated to a social security scheme

          -  Patient information and signature of the informed consent

        Exclusion Criteria:

          -  Contraindications specific to the installation of a KTHIA: thrombosis of the hepatic
             artery, arterial vascular anatomy may compromise a secondary hepatic resection.

          -  Patient immediately eligible for a curative therapy (surgical and/or percutaneous)
             after discussion in CPR

          -  Following alterations in the 6 months prior to inclusion: myocardial infarction,
             angina, severe/unstable angina, coronary artery bypass surgery, congestive heart
             failure NYHA class II, III or IV, stroke or transient ischemic attack

          -  Hypertension not controlled by medical treatment (SBP &gt; 140 mmHg and/or DBP&gt; 90 mmHg
             with blood pressure taken according to the diagram of the HAS)

          -  A history of abdominal fistula, gastrointestinal perforation, intra-abdominal abscess
             or active gastrointestinal bleeding in the 6 months preceding the start of treatment

          -  Progressive gastroduodenal ulcer, wound or fractured bone

          -  Abdominal or major extra-abdominal surgery (except diagnostic biopsy) or irradiation
             in the 4 weeks before starting the treatment

          -  Transplant patients, HIV positive or other immune deficiency syndromes

          -  Any progressive pathology not balanced over the past 6 months: hepatic failure, renal
             failure, respiratory failure

          -  Peripheral neuropathy &gt; 1

          -  Patient with interstitial pneumonitis or pulmonary fibrosis

          -  History of chronic diarrhea or inflammatory disease of the colon or rectum, or
             unresolved occlusion or sub-occlusion in symptomatic treatment

          -  History of malignant pathologies during the past 5 years except basocellular skin
             carcinoma considered in complete remission or in situ cervical carcinoma, properly
             treated

          -  Patient already included in another clinical trial with an experimental molecule

          -  Any known specific contraindication or allergy or hypersensitivity to the drugs used
             in the study (cf RCP Appendix 7)

          -  Known deficit in DPD

          -  QT/QTc range &gt; 450 msec for men and &gt; 470 msec for women

          -  K+ &lt; LNL, Mg2+ &lt; LNL, Ca2+ &lt; LNL

          -  Lack of effective contraception in patients (men and/or women) of childbearing age,
             pregnant or breastfeeding women, women of childbearing age not having had a pregnancy
             test

          -  Persons deprived of liberty or under supervision

          -  Impossibility of undergoing medical monitoring during the trial for geographic, social
             or psychological reasons
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julien TAIEB, MD-PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HEGP, Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marie MOREAU</last_name>
    <phone>+33 (0)380393404</phone>
    <email>marie.moreau@u-bourgogne.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antoine BOUVIER</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de cancérologie de l'Ouest</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Véronique GUERIN-MEYER</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Sainte Catherine</name>
      <address>
        <city>Avignon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laurent MINEUR</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Polyclinique Bordeaux Nord</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cedric LECAILLE</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Sud Francilien</name>
      <address>
        <city>Corbeil-essonnes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Samy LOUAFI</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chu Le Bocage</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sylvain MANFREDI</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Victoire GRANGER</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chd Vendee</name>
      <address>
        <city>La Roche Sur Yon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Roger FAROUX</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Longjumeau</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Samy LOUAFI</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital du Scorff</name>
      <address>
        <city>Lorient</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Joëlle EGRETEAU</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Europeen</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yves RINALDI</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Joseph</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hervé PERRIER</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre d'Imagerie médicale du Confluent- IRIS GRIM</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Marie PASQUIER</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yann TOUCHEFEU</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpial Privé du Confluent Le Confluent Centre Catherine de Sienne</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hélène CASTANIE</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHR</name>
      <address>
        <city>Orleans</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Paul LAGASSE</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ch de Bicetre</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anne THIROT BIDAULT</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gh La Pitie Salpetriere</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olivier DUBREUIL</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>HEGP</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simon PERNOT</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital St Joseph</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nabil BABA HAMED</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Cochin</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Romain CORIAT</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Europeen G Pompidou</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Julien TAIEB</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint Louis</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thomas APARICIO</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH</name>
      <address>
        <city>Perpignan</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Faiza KHEMISSA</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Pessac</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Denis SMITH</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David TOUGERON</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Eugène Marquis</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Samuel LE SOURD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alice GANGLOFF</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint Gregoire - Chp</name>
      <address>
        <city>Saint Gregoire</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laurent MIGLIANICO</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint- Etienne Chu</name>
      <address>
        <city>Saint- Etienne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean Marc PHELIP</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chu Rangueil</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rosine GUIMBAUD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>GR</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michel DUCREUX</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Paul BROUSSE</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mohamed BOUCHAHDA</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 23, 2016</study_first_submitted>
  <study_first_submitted_qc>August 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2016</study_first_posted>
  <last_update_submitted>February 16, 2017</last_update_submitted>
  <last_update_submitted_qc>February 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>colorectal</keyword>
  <keyword>cancer</keyword>
  <keyword>metastasis</keyword>
  <keyword>hepatic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

